Metformin Hydrochloride Perennial Pharma

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Perennial Pharma, is a biguanide presented as a tablet for oral use. It lowers blood glucose in adults with type 2 diabetes mellitus by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving peripheral insulin sensitivity.

GNH USA supplies Metformin Hydrochloride Perennial Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is used in the management of type 2 diabetes mellitus, the primary disorder of glucose metabolism it addresses.

- Type 2 diabetes mellitus (monotherapy): provides baseline glycemic control and reduces HbA1c. - Type 2 diabetes mellitus (combined with other oral antidiabetics): enhances overall glucose lowering when added to agents such as sulfonylureas or DPP‑4 inhibitors. - Type 2 diabetes mellitus (combined with insulin): allows lower insulin doses and improves post‑prandial glucose control.

Metformin Hydrochloride may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: watery stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: long‑term use may reduce absorption.

Metformin Hydrochloride requires careful clinical monitoring to minimize risks.

- Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: contraindicated in acute or chronic liver disease. - Lactic acidosis risk: discontinue before radiographic contrast studies or surgery. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Vitamin B12 monitoring: periodic testing recommended for long‑term therapy. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Iodinated radiographic contrast agents: may precipitate lactic acidosis; withhold metformin before and after the procedure. - Cimetidine: can increase metformin plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance of metformin. - Beta‑blockers: may mask hypoglycemia symptoms when combined with insulin. - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction.